SB-773812 Administered In Adults With Schizophrenia
Status:
Completed
Trial end date:
2007-08-01
Target enrollment:
Participant gender:
Summary
This is a two part study designed to evaluate the safety and efficacy of SB-773812 in the
treatment of acute schizophrenia. Subjects with acute schizophrenia will be randomized in an
adaptive design study to receive placebo, SB-773812 60mg or olanzapine 15mg for 12 weeks in
Part A. An interim analysis will be conducted to assess the efficacy and safety of the
SB-773812 60mg dose compared with placebo. Based on these data, up to two further doses of
SB-773812 will be added to the randomization for Part B.